Aurinia Pharmaceuticals (AUPH) Says Voclosporin Achieves Primary, Secondary Endpoints in Phase IIb Study for LN
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Wall St set for higher open as upbeat earnings obscure Mideast jitters
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- DOJ reportedly preparing antitrust lawsuit against Live Nation, shares slide 9%
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Leerink Affirms Aurinia Pharma (AUPH) at 'Outperform' Following Voclosporin; Says Pipeline Remains Promising
September 30, 2016 2:50 PM EDTLeerink reiterates Aurinia Pharmaceuticals (Nasdaq: AUPH) at Outperform with a price target of $7 after the company announced that in addition to voclosporin (23.7 mg BID) achieving its primary endpoint of Complete Remission (CR) at 24 weeks, both doses of voclosporin when added to the current standard of care of Mycophenolate Mofetil (MMF) and a forced oral corticosteroid taper have met all 24-week pre-specified secondary endpoints vs the control group.
Analyst Joseph... More
